Literature DB >> 10448862

IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.

A Musarò1, K J McCullagh, F J Naya, E N Olson, N Rosenthal.   

Abstract

Localized synthesis of insulin-like growth factors (IGFs) has been broadly implicated in skeletal muscle growth, hypertrophy and regeneration. Virally delivered IGF-1 genes induce local skeletal muscle hypertrophy and attenuate age-related skeletal muscle atrophy, restoring and improving muscle mass and strength in mice. Here we show that the molecular pathways underlying the hypertrophic action of IGF-1 in skeletal muscle are similar to those responsible for cardiac hypertrophy. Transfected IGF-1 gene expression in postmitotic skeletal myocytes activates calcineurin-mediated calcium signalling by inducing calcineurin transcripts and nuclear localization of calcineurin protein. Expression of activated calcineurin mimics the effects of IGF-1, whereas expression of a dominant-negative calcineurin mutant or addition of cyclosporin, a calcineurin inhibitor, represses myocyte differentiation and hypertrophy. Either IGF-1 or activated calcineurin induces expression of the transcription factor GATA-2, which accumulates in a subset of myocyte nuclei, where it associates with calcineurin and a specific dephosphorylated isoform of the transcription factor NF-ATc1. Thus, IGF-1 induces calcineurin-mediated signalling and activation of GATA-2, a marker of skeletal muscle hypertrophy, which cooperates with selected NF-ATc isoforms to activate gene expression programs.

Entities:  

Keywords:  NASA Discipline Cell Biology; Non-NASA Center

Mesh:

Substances:

Year:  1999        PMID: 10448862     DOI: 10.1038/23060

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  171 in total

1.  Critical regulatory domains in intron 2 of a porcine sarcomeric myosin heavy chain gene.

Authors:  K C Chang
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

2.  EMBO Workshop Report: Molecular genetics of muscle development and neuromuscular diseases Kloster Irsee, Germany, September 26-October 1, 1999.

Authors:  T Brand; G Butler-Browne; E M Füchtbauer; R Renkawitz-Pohl; B Brand-Saberi
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

3.  MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type.

Authors:  H Wu; F J Naya; T A McKinsey; B Mercer; J M Shelton; E R Chin; A R Simard; R N Michel; R Bassel-Duby; E N Olson; R S Williams
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

4.  A second calcineurin binding site on the NFAT regulatory domain.

Authors:  S Park; M Uesugi; G L Verdine
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 5.  Meeting Koch's postulates for calcium signaling in cardiac hypertrophy.

Authors:  K R Chien
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 6.  Strength training in the elderly: effects on risk factors for age-related diseases.

Authors:  B F Hurley; S M Roth
Journal:  Sports Med       Date:  2000-10       Impact factor: 11.136

7.  Molecular and quantitative characterisation of the porcine embryonic myosin heavy chain gene.

Authors:  Y M Sun; N da Costa; R Birrell; A L Archibald; H Alzuherri; K C Chang
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

Review 8.  Molecular mechanisms of adipocyte differentiation.

Authors:  Q Tong; G S Hotamisligil
Journal:  Rev Endocr Metab Disord       Date:  2001-10       Impact factor: 6.514

9.  Charge movement and transcription regulation of L-type calcium channel alpha(1S) in skeletal muscle cells.

Authors:  Zhenlin Zheng; Zhong-Min Wang; Osvaldo Delbono
Journal:  J Physiol       Date:  2002-04-15       Impact factor: 5.182

10.  Regulation of myosin heavy chain expression during rat skeletal muscle development in vitro.

Authors:  C E Torgan; M P Daniels
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.